Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech.
The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at between $108 and $111.70 per share, according to a Nov. 13 report from Bloomberg. At the high end of the range, the stake sale is valued at approximately $508 million.
Pfizer and BioNTech collaborated in 2020 to develop a COVID-19 vaccine, one of the pandemic’s most profitable products. Though the companies continue to work together on vaccine formulations, Pfizer’s equity interest in BioNTech was part of their initial partnership.
BioNTech’s U.S.-listed shares fell 3.6%, while Pfizer’s dropped about 0.2%.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
